Published in J Urol on June 01, 2002
Radiotherapy and Hormone Treatment in Prostate Cancer. Dtsch Arztebl Int (2016) 1.21
Brachytherapy with permanent seed implantation. Int J Clin Oncol (2007) 0.94
Brachytherapy in the therapy of prostate cancer - an interesting choice. Contemp Oncol (Pozn) (2013) 0.89
Permanent interstitial brachytherapy for prostate cancer: a current review. World J Urol (2003) 0.78
Downsizing and prostate cancer. Rev Urol (2004) 0.77
Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy. PLoS One (2017) 0.75
Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer. Prostate Cancer (2014) 0.75
Definition of medical event is to be based on the total source strength for evaluation of permanent prostate brachytherapy: A report from the American Society for Radiation Oncology. Pract Radiat Oncol (2011) 0.75
Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy. Radiat Oncol (2012) 0.75
Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression. J Contemp Brachytherapy (2016) 0.75
The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea. Int Neurourol J (2016) 0.75
Interactive-plan technique conquers the disadvantages of volume-reducing hormone therapy in 125I permanent implantation for localized prostate cancer. Int J Clin Oncol (2009) 0.75
Outcomes of lumbar to sacral nerve rerouting for spina bifida. J Urol (2010) 3.94
Optimizing breast cancer treatment efficacy with intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2002) 3.93
A novel DNA-based microfluorimetric method to evaluate antimalarial drug activity. Am J Trop Med Hyg (2004) 2.87
Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys (2003) 2.56
Variability of target and normal structure delineation for breast cancer radiotherapy: an RTOG Multi-Institutional and Multiobserver Study. Int J Radiat Oncol Biol Phys (2009) 2.27
Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol (2005) 2.10
The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys (2002) 2.09
High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol (2004) 1.99
Adaptive replanning strategies accounting for shrinkage in head and neck IMRT. Int J Radiat Oncol Biol Phys (2009) 1.96
What do recent studies on lumpectomy cavity volume change imply for breast clinical target volumes? Int J Radiat Oncol Biol Phys (2008) 1.94
Limited-field radiation therapy in the management of early-stage breast cancer. J Natl Cancer Inst (2003) 1.89
The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol (2010) 1.87
Long-term efficacy and patterns of failure after accelerated partial breast irradiation: a molecular assay-based clonality evaluation. Int J Radiat Oncol Biol Phys (2007) 1.75
Evaluation of a new transcutaneous bilirubinometer. Pediatrics (2004) 1.67
Cone-beam-CT guided radiation therapy: A model for on-line application. Radiother Oncol (2005) 1.66
Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys (2003) 1.65
Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg (2007) 1.61
Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.61
Analysis of treatment efficacy, cosmesis, and toxicity using the MammoSite breast brachytherapy catheter to deliver accelerated partial-breast irradiation: the william beaumont hospital experience. Int J Radiat Oncol Biol Phys (2007) 1.60
Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.58
Online image-guided intensity-modulated radiotherapy for prostate cancer: How much improvement can we expect? A theoretical assessment of clinical benefits and potential dose escalation by improving precision and accuracy of radiation delivery. Int J Radiat Oncol Biol Phys (2004) 1.41
The normal offset of the tricuspid septal leaflet in the fetus. J Ultrasound Med (2002) 1.40
Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.39
Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys (2010) 1.35
Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys (2004) 1.33
Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys (2002) 1.30
Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys (2011) 1.27
Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys (2002) 1.27
A novel assay for quantifying the number of plasmids encapsulated by polymer nanoparticles. Small (2011) 1.25
The American Brachytherapy Society consensus statement for accelerated partial breast irradiation. Brachytherapy (2013) 1.23
Differences in patterns of failure in patients treated with accelerated partial breast irradiation versus whole-breast irradiation: a matched-pair analysis with 10-year follow-up. Int J Radiat Oncol Biol Phys (2008) 1.23
Clinical applications of volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys (2010) 1.23
Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy. Int J Radiat Oncol Biol Phys (2005) 1.21
Image-detected breast cancer: state of the art diagnosis and treatment. J Am Coll Surg (2005) 1.20
Twelve-year clinical outcomes and patterns of failure with accelerated partial breast irradiation versus whole-breast irradiation: results of a matched-pair analysis. Radiother Oncol (2011) 1.19
Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study. Int J Radiat Oncol Biol Phys (2007) 1.17
Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys (2005) 1.17
Four-year efficacy, cosmesis, and toxicity using three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys (2009) 1.14
Computed tomography guided management of interfractional patient variation. Semin Radiat Oncol (2005) 1.12
Geometric and dosimetric evaluations of an online image-guidance strategy for 3D-CRT of prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.11
Risk factors for regional nodal failure after breast-conserving therapy: regional nodal irradiation reduces rate of axillary failure in patients with four or more positive lymph nodes. Int J Radiat Oncol Biol Phys (2003) 1.11
Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol (2003) 1.08
Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer (2003) 1.06
Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J Urol (2005) 1.06
Treatment efficacy with accelerated partial breast irradiation (APBI): final analysis of the American Society of Breast Surgeons MammoSite(®) breast brachytherapy registry trial. Ann Surg Oncol (2013) 1.03
Partial breast irradiation in breast conserving therapy by way of intersitial brachytherapy. Am J Surg (2004) 1.02
Human body contour data based activity recognition. Conf Proc IEEE Eng Med Biol Soc (2013) 1.01
High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data. Int J Radiat Oncol Biol Phys (2011) 1.00
Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study. Am J Surg (2006) 0.99
Interim cosmetic results and toxicity using 3D conformal external beam radiotherapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys (2007) 0.98
Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys (2005) 0.97
Redirection of genetically engineered CAR-T cells using bifunctional small molecules. J Am Chem Soc (2015) 0.96
A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity. Int J Radiat Oncol Biol Phys (2005) 0.96
Five-year outcomes and toxicities using 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Clin Breast Cancer (2012) 0.95
Adaptive radiation therapy for prostate cancer. Semin Radiat Oncol (2010) 0.95
The variability of the clinical target volume for rectal cancer due to internal organ motion during adjuvant treatment. Int J Radiat Oncol Biol Phys (2002) 0.94
Outcome after ipsilateral breast tumor recurrence in patients who receive accelerated partial breast irradiation. Cancer (2012) 0.94
The influence of small bowel motion on both a conventional three-field and intensity modulated radiation therapy (IMRT) for rectal cancer. Cancer Radiother (2004) 0.94
Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? Int J Radiat Oncol Biol Phys (2005) 0.92
Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. Future Oncol (2009) 0.91
Factors associated with the development of breast cancer-related lymphedema after whole-breast irradiation. Int J Radiat Oncol Biol Phys (2011) 0.91
Factors associated with optimal cosmetic results at 36 months in patients treated with accelerated partial breast irradiation (APBI) on the American Society of Breast Surgeons (ASBrS) MammoSite Breast Brachytherapy Registry Trial. Ann Surg Oncol (2009) 0.90
Dosimetric impact of online correction via cone-beam CT-based image guidance for stereotactic lung radiotherapy. Int J Radiat Oncol Biol Phys (2010) 0.90
Matched-pair analysis of prostate cancer patients with a high risk of positive pelvic lymph nodes treated with and without pelvic RT and high-dose radiation using high dose rate brachytherapy. Am J Clin Oncol (2006) 0.89
Cost-efficacy of acceleration partial-breast irradiation compared with whole-breast irradiation. Breast Cancer Res Treat (2013) 0.89
Factors associated with ipsilateral breast failure and distant metastases in patients with invasive breast carcinoma treated with breast-conserving therapy. A clinicopathologic study of 607 neoplasms from 583 patients. Am J Clin Pathol (2003) 0.88
Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation. Int J Radiat Oncol Biol Phys (2005) 0.88
Second-trimester sonography and trisomy 18: the significance of isolated choroid plexus cysts after an examination that includes the fetal hands. J Ultrasound Med (2004) 0.88
Four-dimensional fetal echocardiography with spatiotemporal image correlation (STIC): a systematic study of standard cardiac views assessed by different observers. J Matern Fetal Neonatal Med (2005) 0.88
Multiple Local Recurrent Myxoma. Echocardiography (1998) 0.88
Intraoperative radiation therapy: a critical analysis of the ELIOT and TARGIT trials. Part 2--TARGIT. Ann Surg Oncol (2014) 0.87
Radioembolization of renal cell carcinoma using yttrium-90 microspheres. J Vasc Interv Radiol (2013) 0.86
A cost comparison analysis of adjuvant radiation therapy techniques after breast-conserving surgery. Breast J (2013) 0.86
Comparison of planned versus actual dose delivered for external beam accelerated partial breast irradiation using cone-beam CT and deformable registration. Int J Radiat Oncol Biol Phys (2010) 0.85
Long-term patterns of in-breast failure in patients with early stage breast cancer treated with breast-conserving therapy: a molecular based clonality evaluation. Am J Clin Oncol (2010) 0.85
Image guidance in external beam accelerated partial breast irradiation: comparison of surrogates for the lumpectomy cavity. Int J Radiat Oncol Biol Phys (2007) 0.85
The emerging role of brachytherapy in the management of patients with breast cancer. Semin Radiat Oncol (2002) 0.85
Heterogeneous vancomycin-intermediate susceptibility in a community-associated methicillin-resistant Staphylococcus aureus epidemic clone, in a case of Infective Endocarditis in Argentina. Ann Clin Microbiol Antimicrob (2011) 0.84
Relationship of residual intraluminal to intrathrombotic pressure in a closed aneurysmal sac. J Vasc Surg (2003) 0.83
Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups? Strahlenther Onkol (2006) 0.83
Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys (2005) 0.83